NCT06411730View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

October 28, 2024

Study Completion Date

October 28, 2024

Conditions
Healthy Participants
Interventions
DRUG

BMS-986368

Specified dose on specified days

Trial Locations (1)

92780

Local Institution - 0001, Anaheim

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT06411730 - A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity | Biotech Hunter | Biotech Hunter